Murphy Amanda Louise 4
4 · MAXCYTE, INC. · Filed Nov 16, 2021
Insider Transaction Report
Form 4
MAXCYTE, INC.MXCT
Murphy Amanda Louise
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-11-12$4.42/sh+51,103$225,875→ 51,103 total - Sale
Common Stock
2021-11-12$12.66/sh−51,103$646,964→ 0 total - Sale
Common Stock
2021-11-15$12.16/sh−61,591$748,947→ 0 total - Exercise/Conversion
Common Stock
2021-11-16$4.42/sh+37,306$164,893→ 37,306 total - Sale
Common Stock
2021-11-16$12.08/sh−37,306$450,656→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-12−51,103→ 1,098,897 totalExercise: $4.42Exp: 2030-09-08→ Common Stock (51,103 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-15−61,591→ 1,037,306 totalExercise: $4.42Exp: 2030-09-08→ Common Stock (61,591 underlying) - Exercise/Conversion
Common Stock
2021-11-15$4.42/sh+61,591$272,232→ 61,591 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-16−37,306→ 1,000,000 totalExercise: $4.42Exp: 2030-09-08→ Common Stock (37,306 underlying)
Footnotes (5)
- [F1]This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F5]One-sixteenth (1/16th) of the shares underlying this option vested on December 7, 2020, and the remainder vested or shall vest monthly in forty-five (45) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.